Diabetes
Conditions
Keywords
zinc, diabetes, genetics
Brief summary
The purpose of this study is to evaluate the effect of zinc supplementation on insulin secretion by genotype of SLC30A8.
Detailed description
As diabetes increases at an alarming rate, strategies for prevention of this disease must be developed. For a given individual, there are both biologic (e.g., genetic) and environmental (e.g., lifestyle) factors that comprise her individual risk of diabetes. Researchers can take advantage the accumulating knowledge of these individual factors to design individualized strategies for diabetes risk assessment and prevention. For example, a mutation in a particular gene, SLC30A8, which encodes a zinc transporter, has been shown to increase the risk of diabetes probably through impairment of insulin secretion. In the proposed research project, the investigators aim to conduct a pilot study to see the effect of zinc supplementation on insulin secretion in people with and without this genetic mutation to see if zinc can improve insulin secretion in those with the mutation. The results from this study will help the investigators to plan a larger, more definitive study to determine if zinc supplementation can be used to prevent or treat diabetes in those with this mutation in SLC30A8.
Interventions
DIETARY_SUPPLEMENTZinc acetate
50mg of elemental zinc to be administered 2 times daily orally for 14 days.
Sponsors
Johns Hopkins University
University of Maryland, Baltimore
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* aged 21-70 years * Amish decent * genotyping of rs13266634 of SLC30A8 gene * previously consented to contact for future studies and future use of DNA
Exclusion criteria
* Subject is a first-degree relative of another subject with the same SLC30A8 genotype * diabetes mellitus (by history, treatment or random BG\>200 mg;dl) * gastrointestinal disease causing nausea, vomiting, or diarrhea including inflammatory bowel disease by history. * rheumatoid arthritis by history * albumin \< 3.5 g/dL * hemochromatosis by history * hematocrit \<34% * liver disease by history * alanine aminotransferase or aspartate aminotransferase greater than 2.5 times normal * renal failure by history * estimated glomerular filtration rate \< 60 mL/min by MDRD equation * use of thiazide diuretic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation * use of systemic corticosteroid and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation * use of highly-active antiretroviral medications * use of antipsychotic medications * use of quinolone antibiotics * use of tetracycline antibiotic and unwilling to discontinue if deemed safe in the opinion of the treating physician and study physician for 1 week prior to protocol initiation * use of chelation therapy in the past month * unwilling to withdraw from supplements for 1 week prior to the study and throughout study * abnormal thyroid stimulating hormone (TSH) level * serious disease precluding participation * reported pregnancy or positive urine hCG test * cancer diagnosis in past 2 years * breastfeeding * use of denture adhesive
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in acute insulin response from IVGTT. | 14 days |
Secondary
| Measure | Time frame |
|---|---|
| change in insulin sensitivity | 14 days |
| change in disposition index | 14 days |
| self-report of history of symptoms of anemia or gastrointestinal symptoms during study | 14 days |
| change in serum zinc | 14 days |
| change in urinary zinc | 14 days |
Countries
United States
Outcome results
None listed